{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE282nnn/GSE282968/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282968"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"hepatocellular carcinoma after glucose-free microvesicle treatment","description":"As tumor progression occurs, liver cancer cells are often in a state of nutrient deprivation, particularly lacking glucose. We found that microvesicles secreted by liver cancer cells under glucose-free conditions can promote tumorigenesis and progression. The specific mechanism involves enhancing neutrophil expression of PD-L1 and VEGFA, thereby suppressing T cell cytotoxicity and promoting angiogenesis.This phenotype is abolished after Ezrin knockout in liver cancer cells.","dates":{"publication":"2026/04/01"},"accession":"GSE282968","cross_references":{"GSM":["GSM8653733","GSM8653731","GSM8653732"],"GPL":["28330"],"GSE":["282968"],"taxon":["Mus musculus"]}}